# Dexmethylphenidate
*Source: https://go.drugbank.com/drugs/DB06701*

## Overview

### Description

This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.

### Background

Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002
2
. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant
5
. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Label
,
2
. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture
2
.

### Indication

Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment
4
,
Label
.

### Pharmacodynamics

Dexmethylphenidate is the d-enantiomer of methylphenidate
Label
. This enantiomer is more pharmacologically active than the racemic mixture and may block norepinephrine and dopamine reuptake in synapses
Label
.

### Mechanism of Action

Sodium-dependent dopamine transporter
Inhibitor
Sodium-dependent noradrenaline transporter
Inhibitor

### Absorption

Taking dexmethylphenidate with or without food does not affect patients in a clinically relevant way
4
. 90% of an oral dose is absorbed
Label
but as a result of hepatic first pass metabolism, oral bioavailability of dexmethylphenidate is 23% compared to l-methylphenidate with an oral bioavailability of 5%
4
. Maximum concentration is generally reached in 1-1.5 hours
Label
.

### Metabolism

Dexmethylphenidate is metabolised to the inactive metabolite ritalinic acid by carboxylesterase 1A1 in the liver
Label
,
1
. Other minor pathways metabolise dexmethylphenidate to the inactive metabolites 6-oxo-methylphenidate and p-hydroxy-methylphenidate which are de-esterified and conjugated into other unknown metabolites
4
.
Hover over products below to view reaction partners
Dexmethylphenidate
Ritalinic acid
p-hydroxy-methylphenidate
6-oxo-methylphenidate

### Half-life

The mean terminal half life is approximately 2.2 hours
Label
. However other studies have shown 3.8-3.9 hours
3
, or 5.96 hours after intravenous administration and 5.69 hours following an oral dose
4
.

### Toxicity

There is no difference in effect across genders
3
,
Label
. The difference in effect across racial groups, patients under 6 years, renal impairment, hepatic impairment, pregnancy, lactation, and geriatric patients has not been well studied. Patients with renal impairment are not expected to need dose adjustment as the drug is not mainly cleared renally
Label
. Animal studies in pregnant and lactating rats showed delayed fetal skeletal ossification, and reduced weight gain in male offspring
Label
. Due to these studies, caution must be exercised and the benefits and risks of taking this drug must be weighed
Label
. It is unlikely that dexmethylphenidate is carcinogenic but B6C3F1 mice, which are sensitive to the development of hepatic tumours, developed hepatoblastomas at 2 times the maximum recommended human dose
Label
. Methylpheidate was not found to be mutagenic but is weakly clastogenic in Chinese Hamster Ovary cells
Label
. Methylphenidate does not impair fertility in animal studies
Label
.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Dexmethylphenidate is combined with 1,2-Benzodiazepine.
Acebutolol
Dexmethylphenidate may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Aceclofenac.
Acemetacin
The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Acemetacin.
Acenocoumarol
The serum concentration of the active metabolites of Acenocoumarol can be increased when Acenocoumarol is used in combination with Dexmethylphenidate.

### Food Interactions

Avoid alcohol. Alcohol inhibits the metabolism of dexmethylphenidate.
Take with or without food.

## Chemical Information

**DrugBank ID:** DB06701

**Synonyms:** (+)-threo-methylphenidate
d-threo-methylphenidate
D-TMP
Dexmethylphenidate
Dexméthylphénidate
Dexmethylphenidatum
Dexmetilfenidato
methyl (R)-phenyl[(R)-piperidin-2-yl]acetate

**Chemical Formula:** C
14
H
19
NO
2

**SMILES:** [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1

**Weight:** Average: 233.3062
Monoisotopic: 233.141578857

**IUPAC Name:** methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US5908850
No
1999-06-01
2015-12-04
US
US6355656
No
2002-03-12
2015-12-04
US
US6528530
No
2003-03-04
2015-12-04
US
US6228398
No
2001-05-08
2019-11-01
US
US6635284
No
2003-10-21
2015-12-04
US
US7431944
No
2008-10-07
2015-12-04
US
US5837284
No
1998-11-17
2015-12-04
US
US6730325
No
2004-05-04
2019-11-01
US
US8062667
No
2011-11-22
2029-03-29
US
US8465765
No
2013-06-18
2031-02-15
US
US8778390
No
2014-07-15
2031-02-15
US
US8563033
No
2013-10-22
2031-02-15
US
US8956649
No
2015-02-17
2031-02-15
US
US9040083
No
2015-05-26
2031-02-15
US
US8287903
No
2012-10-16
2031-02-15
US
US7438930
Yes
2008-10-21
2020-06-16
US
US9066869
Yes
2015-06-30
2020-06-16
US
US7247318
Yes
2007-07-24
2020-06-16
US
US7083808
Yes
2006-08-01
2020-06-16
US
US6419960
Yes
2002-07-16
2020-06-16
US
US8580310
Yes
2013-11-12
2020-06-16
US
US9801823
Yes
2017-10-31
2020-06-16
US
US10039719
Yes
2018-08-07
2020-06-16
US
US9498447
No
2016-11-22
2032-03-23
US
US9283214
No
2016-03-15
2032-03-23
US
US9023389
No
2015-05-05
2032-03-23
US
US8927010
No
2015-01-06
2032-03-23
US
US9028868
No
2015-05-12
2032-03-23
US
US9034902
No
2015-05-19
2032-03-23
US
US9603809
No
2017-03-28
2032-03-23
US
US8916588
No
2014-12-23
2032-03-23
US
US10182995
No
2019-01-22
2032-03-23
US
US10111839
No
2018-10-30
2035-10-30
US
US9974752
No
2018-05-22
2035-10-30
US
US10292939
No
2019-05-21
2035-10-30
US
US10292938
No
2019-05-21
2035-10-30
US
US10292937
No
2019-05-21
2032-03-23
US
US10449159
No
2019-10-22
2035-10-30
US
US10463624
No
2019-11-05
2019-12-16
US
US10512613
No
2019-12-24
2035-10-30
US
US10500162
No
2019-12-10
2035-10-30
US
US10507186
No
2019-12-17
2035-10-30
US
US10512612
No
2019-12-24
2035-10-30
US
US10568841
No
2020-02-25
2035-10-30
US
US10617651
No
2020-04-14
2032-03-23
US
US10688060
No
2020-06-23
2035-10-30
US
US10722473
No
2020-07-28
2038-11-19
US
US10881618
No
2021-01-05
2032-03-23
US
US10905652
No
2021-02-02
2032-03-23
US
US10858341
No
2020-12-08
2037-12-09
US
US10954213
No
2021-03-23
2037-12-09
US
US10584112
No
2020-03-10
2037-12-09
US
US9079928
No
2015-07-14
2032-07-27
US
US10584113
No
2020-03-10
2037-12-09
US
US10759778
No
2020-09-01
2037-12-09
US

### Indicated Conditions

1

### Phase 0

1

### Phase 1

11

### Phase 2

7

### Phase 3

19

### Phase 4

8

### Therapeutic Categories

Central Nervous System
Stimulants

### Summary

Dexmethylphenidate
is a norepinephrine-dopamine reuptake inhibitor used in the treatment of ADHD in conjunction with other therapies.

### Brand Names

Azstarys, Focalin

### Generic Name

Dexmethylphenidate

### DrugBank Accession Number

DB06701

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Dexmethylphenidate (DB06701)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Adhd
••••••••••••
Create Account
••••••• ••••••• •••••••• •••••••
Create Account

### Mechanism of action

Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum
5
. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex
5
. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex
5
.
Target
Actions
Organism
A
Sodium-dependent dopamine transporter
inhibitor
Humans
A
Sodium-dependent noradrenaline transporter
inhibitor
Humans
U
Sodium-dependent serotonin transporter
inhibitor
Humans

### Volume of distribution

2.65L/kg when administered intravenously
4
.

### Protein binding

12-15% of dexmethylphenidate is protein bound
Label
. However, other studies have observed 15.2±5.2% protein binding in children and 16.2±1.1% in adults
4
.

### Route of elimination

Dexmethylphenidate is mainly eliminated renally
4
. After 48 hours, 90% of the dose is collected in the urine and 3.3% is collected from feces
4
.

### Clearance

0.40L/hr/kg following an intravenous dose and a renal clearance of 0.005L/hr/kg
4
,
Label
.

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Dexmethylphenidate hydrochloride
1678OK0E08
19262-68-1
JUMYIBMBTDDLNG-OJERSXHUSA-N

### Product Images

Previous
Next

### International/Other Brands

Attenade (Celgene)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Focalin
Tablet
2.5 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US
Focalin
Tablet
10 mg/1
Oral
Sandoz Inc
2001-11-30
2027-09-30
US
Focalin
Tablet
10 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US
Focalin
Tablet
5 mg/1
Oral
Sandoz Inc
2001-11-30
2027-09-30
US
Focalin
Tablet
5 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Dexmethylphenidate HCl
Capsule
30 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
15 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
40 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
25 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
10 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Azstarys
Dexmethylphenidate hydrochloride
(7.8 mg/1)
+
Serdexmethylphenidate chloride
(39.2 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US
Azstarys
Dexmethylphenidate hydrochloride
(5.2 mg/1)
+
Serdexmethylphenidate chloride
(26.1 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US
Azstarys
Dexmethylphenidate hydrochloride
(10.4 mg/1)
+
Serdexmethylphenidate chloride
(52.3 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US

### ATC Codes

N06BA11 — Dexmethylphenidate
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM
N06BA15 — Dexmethylphenidate and serdexmethylphenidate
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Agents that produce hypertension
Antidepressive Agents
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Central Nervous System Stimulation
Centrally Acting Sympathomimetics
Combined Inhibitors of Serotonin/Norepinephrine Reuptake
Dopamine Agents
Dopamine Uptake Inhibitors
Membrane Transport Modulators
Methylphenidate and isomer
Nervous System
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Phenylacetates
Piperidines
Psychoanaleptics
Psychostimulants, Agents Used for ADHD and Nootropics
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Serotonin Agents
Serotonin Modulators

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Piperidines
/
Benzene and substituted derivatives
/
Methyl esters
/
Amino acids and derivatives
/
Monocarboxylic acids and derivatives
/
Dialkylamines
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 1 more
Substituents
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Hydrocarbon derivative
/
Methyl ester
/
Monocarboxylic acid or derivatives
/
Monocyclic benzene moiety
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Secondary aliphatic amine
/
Secondary amine
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
methyl phenyl(piperidin-2-yl)acetate (
CHEBI:51860
)

### Kingdom

Organic compounds

### Super Class

Organic nitrogen compounds

### Class

Organonitrogen compounds

### Sub Class

Amines

### Direct Parent

Aralkylamines

### Alternative Parents

Piperidines
/
Benzene and substituted derivatives
/
Methyl esters
/
Amino acids and derivatives
/
Monocarboxylic acids and derivatives
/
Dialkylamines
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 1 more

### Substituents

Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Hydrocarbon derivative
/
Methyl ester
/
Monocarboxylic acid or derivatives
/
Monocyclic benzene moiety
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Secondary aliphatic amine
/
Secondary amine
show 10 more

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

methyl phenyl(piperidin-2-yl)acetate (
CHEBI:51860
)

### Affected organisms

Humans and other mammals

### UNII

M32RH9MFGP

### CAS number

40431-64-9

### InChI Key

DUGOZIWVEXMGBE-CHWSQXEVSA-N

### InChI

InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1

### Synthesis Reference

Arie Gutman, "Process for the preparation of dexmethylphenidate hydrochloride." U.S. Patent US20040180928, issued September 16, 2004.
US20040180928

### General References

Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76. doi: 10.1124/jpet.104.067116. Epub 2004 Apr 13. [
Article
]
Liu F, Minami H, Silva RR: Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73. [
Article
]
Modi NB, Wang B, Noveck RJ, Gupta SK: Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol. 2000 Oct;40(10):1141-9. [
Article
]
Kimko HC, Cross JT, Abernethy DR: Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999 Dec;37(6):457-70. doi: 10.2165/00003088-199937060-00002. [
Article
]
Tremblay S, Pieper F, Sachs A, Joober R, Martinez-Trujillo J: The Effects of Methylphenidate (Ritalin) on the Neurophysiology of the Monkey Caudal Prefrontal Cortex. eNeuro. 2019 Mar 4;6(1). pii: eN-NWR-0371-18. doi: 10.1523/ENEURO.0371-18.2018. eCollection 2019 Jan-Feb. [
Article
]
Focalin (Dexmethylphenidate) FDA Label [
File
]
Dexmethylphenidate XR FDA Label [
File
]

### External Links

Human Metabolome Database
HMDB0015647
PubChem Compound
154101
PubChem Substance
99443255
ChemSpider
135807
BindingDB
50062915
RxNav
352372
ChEBI
51860
ChEMBL
CHEMBL827
ZINC
ZINC000000896711
PharmGKB
PA10054
PDBe Ligand
A1D5U
Wikipedia
Dexmethylphenidate

### Human Metabolome Database

HMDB0015647

### PubChem Compound

154101

### PubChem Substance

99443255

### ChemSpider

135807

### BindingDB

50062915

### RxNav

352372

### ChEBI

51860

### ChEMBL

CHEMBL827

### ZINC

ZINC000000896711

### PharmGKB

PA10054

### PDBe Ligand

A1D5U

### Wikipedia

Dexmethylphenidate

### PDB Entries

8y2g

### FDA label

Download
(1.11 MB)

### MSDS

Download
(242 KB)

### Dosage Forms

Form
Route
Strength
Tablet
Oral
10 mg
Tablet
Oral
2.5 mg
Tablet
Oral
5 mg
Capsule
Oral
Capsule
Oral
10 mg/1
Capsule
Oral
15 mg/1
Capsule
Oral
20 mg/1
Capsule
Oral
25 mg/1
Capsule
Oral
30 mg/1
Capsule
Oral
35 mg/1
Capsule
Oral
40 mg/1
Capsule
Oral
5 mg/1
Capsule, extended release
Oral
25 mg/1
Capsule, extended release
Oral
30 mg/1
Capsule, extended release
Oral
35 mg/1
Tablet
Oral
10 mg/1
Tablet
Oral
2.5 mg/1
Tablet
Oral
5 mg/1
Capsule, extended release
Oral
15 mg/1
Capsule, extended release
Oral
40 mg/1
Capsule, extended release
Oral
10 mg/1
Capsule, extended release
Oral
20 mg/1
Capsule, extended release
Oral
5 mg/1

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
>203
[MSDS]

### Predicted Properties

Property
Value
Source
logP
2.25
Chemaxon
pKa (Strongest Basic)
9.09
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
2
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
38.33 Å
2
Chemaxon
Rotatable Bond Count
4
Chemaxon
Refractivity
66.73 m
3
·mol
-1
Chemaxon
Polarizability
26.15 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9941
Blood Brain Barrier
+
0.9663
Caco-2 permeable
+
0.6564
P-glycoprotein substrate
Substrate
0.5466
P-glycoprotein inhibitor I
Non-inhibitor
0.7964
P-glycoprotein inhibitor II
Non-inhibitor
0.9601
Renal organic cation transporter
Inhibitor
0.532
CYP450 2C9 substrate
Non-substrate
0.7897
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.5985
CYP450 1A2 substrate
Non-inhibitor
0.592
CYP450 2C9 inhibitor
Non-inhibitor
0.897
CYP450 2D6 inhibitor
Non-inhibitor
0.5245
CYP450 2C19 inhibitor
Non-inhibitor
0.9265
CYP450 3A4 inhibitor
Non-inhibitor
0.8539
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9328
Ames test
Non AMES toxic
0.9133
Carcinogenicity
Non-carcinogens
0.9648
Biodegradation
Not ready biodegradable
0.5759
Rat acute toxicity
2.7718 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8466
hERG inhibition (predictor II)
Non-inhibitor
0.7491
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0089-9610000000-8e4c1241e36274356032
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-4190000000-fef041a243a714b6bcaf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001r-9120000000-b5db236b260a5c8e3151
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0089-3790000000-1d766bcf3e602b1e5a3b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014l-4920000000-775709067ea58a06f13b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-052f-9200000000-bc89321ee3ca13496a53
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9100000000-da8a2bb07df6a5f27f1a
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
163.9031387
predicted
DarkChem Lite v0.1.0
[M-H]-
154.58199
predicted
DeepCCS 1.0 (2019)
[M+H]+
164.2831387
predicted
DarkChem Lite v0.1.0
[M+H]+
156.94
predicted
DeepCCS 1.0 (2019)
[M+Na]+
164.1948387
predicted
DarkChem Lite v0.1.0
[M+Na]+
163.03313
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

No

### Actions

Substrate

### General Function

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672). Essential for serotonin homeostasis in the central nervous system. In the developing somatosensory cortex, acts in glutamatergic neurons to control serotonin uptake and its trophic functions accounting for proper spatial organization of cortical neurons and elaboration of sensory circuits. In the mature cortex, acts primarily in brainstem raphe neurons to mediate serotonin uptake from the synaptic cleft back into the pre-synaptic terminal thus terminating serotonin signaling at the synapse (By similarity). Modulates mucosal serotonin levels in the gastrointestinal tract through uptake and clearance of serotonin in enterocytes. Required for enteric neurogenesis and gastrointestinal reflexes (By similarity). Regulates blood serotonin levels by ensuring rapid high affinity uptake of serotonin from plasma to platelets, where it is further stored in dense granules via vesicular monoamine transporters and then released upon stimulation (PubMed:17506858, PubMed:18317590). Mechanistically, the transport cycle starts with an outward-open conformation having Na1(+) and Cl(-) sites occupied. The binding of a second extracellular Na2(+) ion and serotonin substrate leads to structural changes to outward-occluded to inward-occluded to inward-open, where the Na2(+) ion and serotonin are released into the cytosol. Binding of intracellular K(+) ion induces conformational transitions to inward-occluded to outward-open and completes the cycle by releasing K(+) possibly together with a proton bound to Asp-98 into the extracellular compartment. Na1(+) and Cl(-) ions remain bound throughout the transport cycle (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672). Additionally, displays serotonin-induced channel-like conductance for monovalent cations, mainly Na(+) ions. The channel activity is uncoupled from the transport cycle and may contribute to the membrane resting potential or excitability (By similarity)

### Specific Function

hydrolase activity

### Gene Name

CES1A1a

### Uniprot ID

Q6LAP9

### Uniprot Name

Carboxylesterase

### Molecular Weight

1908.25 Da

